@lizziechiang@lizziechiang We saw your tweet and would like to know more about your circumstances. Please provide your contact info and social media username to [email protected] so that we can help.
Novartis delivered solid sales growth and core margin expansion in Q3, as priority brands and launches more than offset generic erosion.
We have raised our full-year 2026 guidance* for core operating income.
Link to press release: https://t.co/vGlqKR4Lds
#NVSQ326
#NVSQ326 Novartis social media posts on Q3 2026 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information.
#NVSQ326 Novartis social media posts on Q3 2026 contain non-IFRS measures. An explanation of non-IFRS measures is available on our website Novartis quarterly financial results | Novartis.
$NVS $NOVN
Dear Mark Weatherall,
Thank you for your enquiry. We recommend you contact our local office in the United Kingdom for this matter. They can be reached by phone at +44 1276 692255 from Monday – Friday, 09.00am to 17.00pm GMT+1. The local team will follow up with you directly once you contact them.
Kind regards,
Novartis Community Manager
@KaulSurend58285@KaulSurend58285 We saw your tweet and would like to know more about your circumstances. Please provide your contact info and social media username to [email protected] so that we can help.
@LlamaTerra85@LlamaTerra85 We saw your tweet. We take product safety seriously and want to know more. Please provide your contact info and social media username to [email protected] so we can follow up.
@chrischofiel1@chrischofiel1 We saw your tweet and would like to know more about your circumstances. Please provide your contact info and social media username to [email protected] so that we can help.
@aro0o1122@aro0o1122 We saw your tweet. We take product safety seriously and would like to know more about your circumstances. Please provide your contact info, social media username and location to [email protected] so we can follow up.
@malakarenina@malakarenina We saw your tweet. We are sorry to hear about your experience. Please provide your contact info and social media username to [email protected] so we can follow up.
@Lau_2720 Dear Laura,
Thank you for your enquiry. For product related information we recommend you contact our local office in Ecuador by phone at +593 4 220 2700. For additional contact information, visit this page: https://t.co/zBgapg8BAg
Kind regards,
Novartis Community Manager
Hi Project Umbreon,
Thank you for your message. We are committed to highly ethical business practices and do not tolerate any misconduct of our associates. To process your enquiry, please contact our SpeakUp office by using our reporting tool i-Sight Portal here https://t.co/yWsQEKUqsT
Kind regards,
Novartis Community Manager
@viishh@viishh We saw your tweet and would like to know more about your circumstances. Please provide your contact info and social media username to [email protected] so that we can help.
@PabloWeather Dear Pablo Pereira,
Thank you for your message. We recommend you contact our local office near you for more information. For information on how to contact Novartis country offices, visit this page: https://t.co/5qSgj6Zi4i
Kind regards,
Novartis Community Manager
Dear S ROY,
Thank you for your enquiry. We recommend you contact our local office in India for this matter. They can be reached by phone at +91 22 5024 3000 or +91 40 6758 1000. The local team will follow up with you directly once you contact them.
Kind regards,
Novartis Community Manager
Hi @bouzas_cris,
Thank you for your enquiry. We recommend you contact our local office in Argentina for this matter. They can be reached by phone at +54 11 4703-7000 from Monday – Friday, 9:00am - 06:00pm (GMT-3). The local team will follow up with you directly once you contact them.
Kind regards,
Novartis Community Manager
@Brnpph Thanks for reaching out. We are sorry to hear about your experience. Please provide your contact info and social media username to [email protected] so we can follow up.
@minieb1 Hi @minieb1, Thanks for getting in touch. We understand your concern and want to make sure you get the right support. Please reach out to our ENTRESTO® Patient Support at 1 888 ENTRESTO (1-888-368-7378), and someone will be happy to help.
@leonesjeisson@leonesjeisson We saw your tweet. We are sorry to hear about your experience. Please provide your contact info and social media username to [email protected] so we can follow up.
#Investors:
Novartis delivered strong growth in priority brands and recent launches during Q1 2026, while US generic erosion weighed on results as expected. We remain on track to deliver our full year guidance.
Press release: https://t.co/knIbxtaBMP
IR Webcast: https://t.co/Lv4xwJj07V
#NVSQ126 $NVS $NOVN